Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | C1S | P09871 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109724 | 1.00 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL8321303 | 1.00 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL28530493 | 0.89 | CTSL (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL28127816 | 0.82 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL3725357 | 0.82 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| Bromobenzene SCHEMBL28232899 | 0.81 | CYP2C19 (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL6815084 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL6815081 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL17008402 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 | |
| SCHEMBL749086 | 0.78 | C1S (0.56) | NPC1RAB9ASMN1; SMN2CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927218-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | NPC1 2025/4885RAB9A 654/4885SMN1; SMN2 4238/4885 |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | NPC1 3127/4885RAB9A 591/4885SMN1; SMN2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.